| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Accounting > Standard Cost Accounting in Determining the Estimate Versus Actual |
|
Just Other Articles - Standard Cost Accounting in Determining the Estimate Versus Actual
Cost accounting in manufacturing answers the simple question: “Am I making money on this job, and if not then why not?”. Cost accounting is a bridge between financial and According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product management accounting and is a technique used to address the demands of both. It is a systematic application that takes all events in the supply chain and translates them ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in into financial values for analyses by various people both inside and outside the company operations. The most important results of the analyses are findings by which manag lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ement can reduce manufacturing costs while improving profitability, especially in the multi-sequence operations of manufacturing. While there are several ways to approach here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ost accounting (e.g., activity-based, throughput, etc.), the generally accepted accounting principles most in line with manufacturing operations are standard cost accoun d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ting and weighted average cost accounting. In both standard cost and weighted average cost accounting, managers can best assess production profit results as th ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc y are related to a formula for the “standard cost” of manufacturing a product. In general terms, the computation of manufacturing cost involves many methods and techni easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ques to define the components of cost, as well as determining what will be the basis of cost measurement such as historical cost, market value, and/or actual cost. For man nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically gers, the simple point of cost accounting is to determine why production costs are different than what they were planned (or estimated) to be, and then to take the appropri and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ate corrective action. In an integrated enterprise resource planning operation (ERP), where work orders, shop floor routers, and travelers define the job sequencing for a ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi enerated sales order, each aspect of the sequence is reviewed in terms of actual versus estimated cost to attempt to discover those production steps than are deviating the ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a most from the planned cost. In focusing so closely upon the production sequence, each and every step can be macroanalyzed in terms of cost as it is related to variables su dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod h as volume of output, material, and labor time for production. For example, to discover actual versus estimate discrepancies in a particular work center or production cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin sequence, management can look to things such as scrap piece counts, set-up times/cost, and material costs as they concern specific sequences. As such data is accumulated, tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen it is easier to come to an understanding as to what specific aspect or sequence in production is costing more than the estimate, and why it is doing so. For those manufact t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel urers utilizing more robust ERP software systems, managers can quickly and easily see actual dollar costs against individual production activities, as well as finding oppor ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust unities to streamline operations and reduce costs. If needed, as a result of cost accounting a manager can even determine whether they should eliminate the entire producti y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products on activity, especially if there is no value added or profit to be made. With accurate and regular job cost accounting facilitated by ERP software, the modern manufact . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de rer gains a competitive edge through the routine maintenance of cost efficiencies. Indeed, as corrections, as a result of cost accounting, are made in the production syste elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip m to alleviate inefficient or non-profitable sequences, actual costs come into closer alignment with estimated costs, and in doing so provide a more predictable bottom-line tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Cartesis Business Performance Management Solutions Pros and Cons of Traditional Office Leasing versus Renting a Business Center Accounting Outsourcing India is Extremely Popular
|